$S1 Episode 4: Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?$

S1 Episode 4: Triple-Class Refractory Multipl...

Up next

S1 Episode 5: Multiple Myeloma Therapies: A Glimpse Into the Future

Drs Joseph Mikhael and Nina Shah discuss the exciting future in multiple myeloma in which bispecifics, CELMoDs, modakafusp, and easily delivered CAR T-cell therapy all may play a role. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape ... Show more

. 24min 27sec

S1 Episode 6: Disparities in Multiple Myeloma: Exposing the Problem and Paving a Path Forward

Drs Joseph Mikhael and Brandon Blue reveal the impact of disparities in multiple myeloma and pave a path forward to culturally competent care. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/viewarticle/964342). The topics and d ... Show more

. 25min 18sec

Recommended Episodes

S1 Episode 6: New and Emerging Therapies in HIV Treatment

Medscape InDiscussion: HIV

Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/vie ... Show more

. 21min 17sec

S1 Episode 3: Antiretroviral Therapy, Maintenance, and Switching

Medscape InDiscussion: HIV

Drs Michael Saag and Constance Benson discuss antiretroviral therapy, maintenance, and switching. Relevant disclosures can be found with the episode show notes on Medscape.com ( https://www.medscape.com/viewarticle/963238). The topics and discussions are planned, produced, and rev ... Show more

. 22min 31sec

Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill

BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ... Show more

. 1h 0min

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation

Blood Podcast

In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show more

. 20min 5sec